Pharma BD Deal Intelligence
Three Phase 2 trials showed EXC-001 produced highly significant 24-week scar improvement vs placebo on Physician Assessment (p<0.001), Subject Assessment…
Pfizer to pick up antisense firm Excaliard, an Isis spinout developing EXC 001 for excessive skin scarring; terms were undisclosed though contingent milestone…
The article presents the deal facts and market opportunity for Excaliard's anti-scarring drug neutrally, citing Pfizer's stated strategy to complement its…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Pfizer acquired Excaliard for undisclosed upfront plus contingent payments. Isis (now Ionis) entitled to up to $14M as a former licensor. Deal added EXC-001 antisense fibrosis candidate to Pfizer pipeline. Below clear $250M threshold per public terms but strategically notable platform deal.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Excaliard Pharmaceuticals, Inc. (this deal) | 2011 | — | 18 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2011 deals · Pfizer Inc. deals · Dermatology deals